IL156264A0 - Isoindolin-1-one glucokinase activators - Google Patents

Isoindolin-1-one glucokinase activators

Info

Publication number
IL156264A0
IL156264A0 IL15626401A IL15626401A IL156264A0 IL 156264 A0 IL156264 A0 IL 156264A0 IL 15626401 A IL15626401 A IL 15626401A IL 15626401 A IL15626401 A IL 15626401A IL 156264 A0 IL156264 A0 IL 156264A0
Authority
IL
Israel
Prior art keywords
isoindolin
glucokinase activators
glucokinase
activators
diabetes
Prior art date
Application number
IL15626401A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL156264A0 publication Critical patent/IL156264A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
IL15626401A 2000-12-13 2001-12-07 Isoindolin-1-one glucokinase activators IL156264A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25527300P 2000-12-13 2000-12-13
US31871501P 2001-09-13 2001-09-13
PCT/EP2001/014404 WO2002048106A2 (fr) 2000-12-13 2001-12-07 Activateurs de l'isoindoline-1-one glucokinase

Publications (1)

Publication Number Publication Date
IL156264A0 true IL156264A0 (en) 2004-01-04

Family

ID=26944583

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15626401A IL156264A0 (en) 2000-12-13 2001-12-07 Isoindolin-1-one glucokinase activators
IL156264A IL156264A (en) 2000-12-13 2003-06-02 Isoindolin-1-On as glucokinase activators, their preparation process and pharmaceutical preparations

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL156264A IL156264A (en) 2000-12-13 2003-06-02 Isoindolin-1-On as glucokinase activators, their preparation process and pharmaceutical preparations

Country Status (36)

Country Link
US (1) US6482951B2 (fr)
EP (1) EP1349856B1 (fr)
JP (1) JP4021766B2 (fr)
KR (1) KR100520651B1 (fr)
CN (1) CN1247574C (fr)
AT (1) ATE297922T1 (fr)
AU (2) AU3841502A (fr)
BG (1) BG107903A (fr)
BR (1) BR0116169A (fr)
CA (1) CA2430579C (fr)
CY (1) CY1105587T1 (fr)
CZ (1) CZ20031882A3 (fr)
DE (1) DE60111570T2 (fr)
DK (1) DK1349856T3 (fr)
EG (1) EG24358A (fr)
ES (1) ES2243578T3 (fr)
HK (1) HK1063314A1 (fr)
HR (1) HRP20030450B1 (fr)
HU (1) HUP0400587A3 (fr)
IL (2) IL156264A0 (fr)
MA (1) MA26973A1 (fr)
MX (1) MXPA03005170A (fr)
MY (1) MY136741A (fr)
NO (1) NO325810B1 (fr)
NZ (1) NZ526236A (fr)
PA (1) PA8534601A1 (fr)
PE (1) PE20020593A1 (fr)
PL (1) PL366006A1 (fr)
PT (1) PT1349856E (fr)
RS (1) RS50933B (fr)
RU (1) RU2249590C2 (fr)
SI (1) SI1349856T1 (fr)
SK (1) SK8732003A3 (fr)
TW (1) TWI294876B (fr)
UY (1) UY27069A1 (fr)
WO (1) WO2002048106A2 (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
KR20050074959A (ko) 2002-10-03 2005-07-19 노파르티스 아게 제ii형 당뇨병 치료에 유용한 글루코키나아제 활성인자로서의 치환된 (티아졸-2-일)-아미드 또는 술폰아미드
ES2293005T3 (es) 2002-10-03 2008-03-16 F. Hoffmann-La Roche Ag Indol-3-carboxamidas como activadores de la glucocinasa.
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
WO2004063194A1 (fr) * 2003-01-06 2004-07-29 Eli Lilly And Company Composes heteroaryle
PL378117A1 (pl) * 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
JP4621198B2 (ja) * 2003-02-11 2011-01-26 プロシディオン・リミテッド トリ(シクロ)置換アミドグルコキナーゼ活性化化合物
US7320992B2 (en) * 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
AU2005229416B2 (en) 2004-04-02 2009-03-26 Novartis Ag Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful the treatment of type 2 diabetes
EP1737870A1 (fr) * 2004-04-02 2007-01-03 Novartis AG Derives thiazolopyridine, compositions pharmaceutiques les contenant et procedes de traitement de troubles a mediation par glucokinase
JPWO2007026761A1 (ja) * 2005-08-31 2009-03-12 アステラス製薬株式会社 チアゾール誘導体
JP2007063225A (ja) * 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
CN101272784A (zh) 2005-09-29 2008-09-24 塞诺菲-安万特股份有限公司 苯基-和吡啶基-1,2,4-噁二唑酮衍生物、它们的制备方法和它们作为药物的用途
GT200600428A (es) * 2005-09-30 2007-05-21 Compuestos organicos
GT200600429A (es) * 2005-09-30 2007-04-30 Compuestos organicos
EP1960385A1 (fr) * 2005-11-01 2008-08-27 Janssen Pharmaceutica N.V. Dihydroisoindolones substitutées modulateurs utilisées en tant que allostériques de la glucokinase
EP1951706A1 (fr) * 2005-11-01 2008-08-06 Janssen Pharmaceutica N.V. Dihydroisoindolones utilisées comme modulateurs allostériques de la glucokinase
CA2627910A1 (fr) * 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Cycloalkylpyrrolones substitues utilises en tant que modulateurs allosteriques de glucokinase
JP2009513711A (ja) * 2005-11-01 2009-04-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ グルコキナーゼのアロステリックモジュレーターとしての置換ピロロン
EP1948644A1 (fr) * 2005-11-03 2008-07-30 Prosidion Limited Amides a substitution tricyclo
JP2009515997A (ja) * 2005-11-18 2009-04-16 タケダ サン ディエゴ インコーポレイテッド グルコキナーゼ活性剤
JP5302012B2 (ja) * 2006-03-08 2013-10-02 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP2049518B1 (fr) * 2006-05-31 2011-08-31 Takeda San Diego, Inc. Derives de l'indazole et de l'isoindazole comme agents de l'activation de glucokinase
WO2008074694A1 (fr) * 2006-12-20 2008-06-26 F. Hoffmann-La Roche Ag Cristallisation d'activateurs de glucokinase
EP2091947A2 (fr) 2006-12-20 2009-08-26 Takeda San Diego, Inc. Activateurs de glucokinase
TW200831081A (en) * 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
EP2116533B1 (fr) * 2007-03-07 2013-07-10 Kyorin Pharmaceutical Co., Ltd. Activateur de glucokinase
US8173645B2 (en) * 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
PE20091313A1 (es) * 2008-01-15 2009-09-03 Lilly Co Eli (r)-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida cristalina
PT2231640E (pt) * 2008-01-24 2012-08-23 Merck Patent Gmbh Derivados beta-aminoácido para o tratamento de diabetes
PT2275414E (pt) * 2008-04-28 2015-09-09 Teijin Pharma Ltd Derivado de amida do ácido ciclopentacrílico
PE20141375A1 (es) 2008-05-16 2014-10-23 Takeda San Diego Inc Activadores de glucoquinasa
EP2344458A1 (fr) * 2008-09-11 2011-07-20 Pfizer Inc. Dérivés d'amides d'hétéroaryles et leur utilisation comme activateurs de la glucokinase
AU2011235212B2 (en) 2010-03-31 2014-07-31 The Scripps Research Institute Reprogramming cells
US8178689B2 (en) * 2010-06-17 2012-05-15 Hoffman-La Roche Inc. Tricyclic compounds
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
MX357121B (es) 2011-03-01 2018-06-27 Synergy Pharmaceuticals Inc Star Proceso de preparacion de agonistas c de guanilato ciclasa.
US8470866B2 (en) * 2011-05-03 2013-06-25 Hoffmann-La Roche Inc. Isoindolinone derivatives
LT3004076T (lt) * 2013-05-27 2020-01-10 F. Hoffmann-La Roche Ag Nauji 3,4-dihidro-2h-izochinolin-1-ono ir 2,3-dihidro-izoindol-1-ono junginiai
BR112015030326A2 (pt) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
ES2901114T3 (es) 2014-08-29 2022-03-21 Tes Pharma S R L Inhibidores de ácido alfa-amino-beta-carboximucónico semialdehído descarboxilasa
KR20190065312A (ko) 2016-10-14 2019-06-11 테스 파마 에스.알.엘. 알파-아미노-베타-카복시뮤콘산 세미알데하이드 데카복실라제의 저해제
WO2020104456A1 (fr) 2018-11-20 2020-05-28 Tes Pharma S.R.L Inhibiteurs de la semialdéhyde décarboxylase de l'acide alpha-amino-bêta-carboxymuconique

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2687147A1 (fr) * 1992-02-11 1993-08-13 Union Pharma Scient Appl Nouveaux derives d'alpha-amino n-pyridyl benzene propanamide, leurs procedes de preparation, compositions pharmaceutiques les contenant.
ES2226811T3 (es) 1999-03-29 2005-04-01 F. Hoffmann-La Roche Ag Activadores de glucoquinasa.
EP1280801B1 (fr) 2000-05-03 2005-09-07 F. Hoffmann-La Roche Ag Activateurs de glucokinase contenant de l'hydantoine
EP1282611B1 (fr) 2000-05-08 2004-10-20 F. Hoffmann-La Roche Ag Phenylacetamides substitues et leur utilisation en tant qu'activateurs de la glucokinase

Also Published As

Publication number Publication date
AU3841502A (en) 2002-06-24
EP1349856A2 (fr) 2003-10-08
EG24358A (en) 2009-03-04
TWI294876B (en) 2008-03-21
PL366006A1 (en) 2005-01-24
MXPA03005170A (es) 2003-09-22
PT1349856E (pt) 2005-09-30
MA26973A1 (fr) 2004-12-20
JP4021766B2 (ja) 2007-12-12
WO2002048106A2 (fr) 2002-06-20
RS50933B (sr) 2010-08-31
PE20020593A1 (es) 2002-07-06
HUP0400587A3 (en) 2011-03-28
NO20032674D0 (no) 2003-06-12
US20020082260A1 (en) 2002-06-27
WO2002048106A3 (fr) 2002-11-28
HUP0400587A2 (hu) 2004-06-28
CY1105587T1 (el) 2010-07-28
NO325810B1 (no) 2008-07-21
HRP20030450B1 (en) 2006-02-28
NO20032674L (no) 2003-06-12
JP2004521095A (ja) 2004-07-15
CN1481382A (zh) 2004-03-10
SK8732003A3 (en) 2004-04-06
MY136741A (en) 2008-11-28
ES2243578T3 (es) 2005-12-01
UY27069A1 (es) 2002-07-31
RU2249590C2 (ru) 2005-04-10
US6482951B2 (en) 2002-11-19
BG107903A (bg) 2004-02-27
NZ526236A (en) 2004-12-24
CN1247574C (zh) 2006-03-29
KR20030064817A (ko) 2003-08-02
CA2430579C (fr) 2010-01-26
SI1349856T1 (en) 2005-10-31
BR0116169A (pt) 2003-12-23
YU47703A (sh) 2006-05-25
KR100520651B1 (ko) 2005-10-11
EP1349856B1 (fr) 2005-06-15
DK1349856T3 (da) 2005-10-17
HRP20030450A2 (en) 2005-04-30
PA8534601A1 (es) 2002-08-26
HK1063314A1 (en) 2004-12-24
AU2002238415B2 (en) 2007-01-04
DE60111570D1 (de) 2005-07-21
CZ20031882A3 (cs) 2003-12-17
CA2430579A1 (fr) 2002-06-20
DE60111570T2 (de) 2006-05-11
IL156264A (en) 2010-11-30
ATE297922T1 (de) 2005-07-15

Similar Documents

Publication Publication Date Title
EG24358A (en) Isoindolin-1-one glucokinase avtivators
MY180762A (en) Combination therapy comprising glucose reabsorption inhibitors and ppar modulators.
MY135222A (en) Substituted phenylacetamides and their use as glucokinase activators
MY136764A (en) Indole-3-carboxamides as glucokinase (gk) activators
MXPA05008406A (es) Compuestos de amida tri(ciclo)-sustituida.
MY136926A (en) Glucokinase activators
WO2001083465A3 (fr) Activateurs heteroaromatiques de la glucokinase a base d'alkynyle-phenyle
PT1311504E (pt) Tetrazolil-fenil-acetamidas activadoras da glucoquinase
JO2180B1 (en) Glucokinase Trans olivine steroids
IL144948A0 (en) Electroactive pore
PT1282611E (pt) Fenilacetamidas substituidas e sua utilizacao como activadores da glucocinase
DE60121988D1 (de) Kombinationstherapie mit antidiabetischen und antikonvulsiven mitteln
MXPA02008722A (es) Inhibidores novedosos de aril fructosa-1,6-bisfosfatasa.
UA72927C2 (uk) Композиція для лікування печінково-клітинного раку, що містить доцетаксель
RS20050733A (en) Benzo/1,2,5/thiadiazole compounds
WO2002024181A3 (fr) Utilisation de la melatonine pour induire une anesthesie generale
JO2238B1 (en) Glycine stimulants iswindline 1- on
EP1251847A4 (fr) Nouvel emploi de la prodigiosine pour traiter le diabete
MXPA04000418A (es) Tratamiento de dolor cronico con 3-heterocicloxi- y -cicloalquiloxi-3-fenilpropanaminas.
UA70017A (en) Method for conservative treatment of chronic tonsillitis in adults
MXPA04003673A (es) Uso de aplidina para el tratamiento de cancer pancreatico.
MD1919G2 (ro) Remediu medicamentos
UA32466C2 (uk) Комплексний інфузійний препарат "реосорбілакт"
ZA200107918B (en) The treatment of rubber.
RS20060323A (en) Substituted indole-o-glucosides